FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person*     Stewart Edward J.			<u> </u>	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [ MACK ]						NC (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify				ner		
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201				0	3. Date of Earliest Transaction (Month/Day/Year) 02/11/2014							SVP & Pres, Healthcare Sol					
(Street) CAMBR (City)		1A State)	02139 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	) 【 Form fil	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Fransaction te Conth/Day/		2A. Deem Execution if any (Month/Da	Date	Cod	e (Inst	n Dispose	(A) c	str. 3, 4 and 5	Beneficia	ties Form (D) or I Following ed action(s)		: Direct   I Indirect   E str. 4)   C	. Nature of ndirect Beneficial Ownership Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Conversion or Exercise (Instr. 3)  2.		Code	Fransaction Code (Instr. 3) A		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	oii(s)		
Stock Option (right to buy)	\$5.02	02/11/2014		A		125,000		(1)		02/10/2024	Common Stock	125,000	\$0	125,00	00	D	

## Explanation of Responses:

1. This option vests as to 1/12th of the total number of shares on 5/11/14 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/11/17.

/s/ Jeffrey A. Munsie, attorneyin-fact

02/13/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.